For instance, EZH2 inhibition in patient samples, mouse models, and human SCLC cell lines activates the PRC2-mediated MHC-I antigen processing pathway, restoring T-cell-mediated tumor immunity (46). This evidence concerns the gene EZH2 and small cell lung carcinoma.